GUIDELINE

European guideline (EuroGuiDerm) on atopic eczema – part II: non-systemic treatments and treatment recommendations for special AE patient populations

A. Wollenberg,1,2,* M. Kinberger,3 B. Arents,4 N. Aszodi,1 G. Avila Valle,3 S. Barbarot,5 T. Bieber,6 H.A. Brough,7 P. Calzavara Pinton,6 S. Christen-Zach,9 M. Deleuran,10 M. Dittmann,3 C. Dressler,3 A.H. Fink-Wagner,11 N. Fosse,12 K. Gáspar,13 L. Gerbens,14 U. Gieler,15 G. Girolomoni,16 S. Gregoriou,17 C.G. Mortz,18 A. Nast,3 U. Nygaard,19 M. Redding,20 E.M. Rehbinder,21 J. Ring,22 M. Rossi,23 E. Serra-Baldrich,24 D. Simon,25 Z.Z. Szalai,26 J.C. Szepietowski,27 A. Torrelo,28 T. Werfel,29 C. Flohr30,31,*

1Department of Dermatology and Allergy, LMU Munich, Munich, Germany
2Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Department of Dermatology, Brussels, Belgium
3Department of Dermatology, Venereology and Allergology, Division of Evidence-Based Medicine (dEBM), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
4European Federation of Allergy and Airways Diseases Patients’ Associations (EFA), Brussels, Belgium
5Department of Dermatology, CHU Nantes, UMR 1280 PHAN, INRAE, Nantes Université, Nantes, France
6Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany
7Children’s Allergy Service, Evelina London Children’s Hospital, Guy’s and St. Thomas’ NHS Foundation Trust, London, and Paediatric Allergy Group, Department of Women and Children’s Health, School of Life Course Sciences, King’s College London, London, UK
8Dermatology Department, University of Brescia, Brescia, Italy
9University Hospital Lausanne, Lausanne, Switzerland
10Aarhus University Hospital, Aarhus, Denmark
11Global Allergy and Airways diseases Patient Platform GAAPP, Vienna, Austria
12Department of Dermatology, University Hospital Basel, Basel, Switzerland
13Department of Dermatology of the University of Debrecen, Debrecen, Hungary
14Department of Dermatology, Amsterdam UMC (University Medical Centers), Amsterdam, The Netherlands
15Department Dermatology, University of Giessen, Giessen, Germany
16Dermatology and Venereology Section, Department of Medicine, University of Verona, Verona, Italy
17Faculty of Medicine, National and Kaposiassian University of Athens, Athens, Greece
18Department of Dermatology and Allergy Centre, Odense University Hospital, University of Southern Denmark, Odense, Denmark
19Department of Dermato-Venerology, Aarhus University Hospital, Aarhus, Denmark
20Eczema Outreach Support (UK), Linlithgow, UK
21Dermatology Department, Oslo University Hospital, Oslo, Norway
22Department Dermatology Allergology Biederstein, Technical University Munich, Munich, Germany
23Dermatology Unit, Spedali Civili Hospital Brescia, Brescia, Italy
24Dermatology, Hospital of Sant Pau, Barcelona, Spain
25Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
26Pediatric Dermatology Unit, Heim Pál National Children’s Institute Budapest, Budapest, Hungary
27Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland
28Hospital Infantil Niño Jesús, Madrid, Spain
29Hannover Medical School, Hanover, Germany
30St John’s Institute of Dermatology, King’s College London, London, UK
31Guy’s & St Thomas’ NHS Foundation Trust, London, UK

*Correspondence: A. Wollenberg. E-mail: willenberg@lrz.uni-muenchen.de and C. Flohr. E-mail: carsten.flohr@kcl.ac.uk

Abstract

The evidence- and consensus-based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. Four consensus conferences were held between December 2020 and July 2021. Twenty-nine experts (including clinicians and patient representatives) from 12 European countries participated. This second part of the guideline includes recommendations and detailed information on basic therapy with emollients and moisturizers, topical anti-inflammatory treatment, antimicrobial and antipruritic treatment and UV phototherapy. Furthermore, this part of the guideline covers techniques for avoiding provocation factors, as well as dietary...
interventions, immunotherapy, complementary medicine and educational interventions for patients with atopic eczema and deals with occupational and psychodermatological aspects of the disease. It also contains guidance on treatment for paediatric and adolescent patients and pregnant or breastfeeding women, as well as considerations for patients who want to have a child. A chapter on the patient perspective is also provided. The first part of the guideline, published separately, contains recommendations and guidance on systemic treatment with conventional immunosuppressive drugs, biologics and janus kinase (JAK) inhibitors, as well as information on the scope and purpose of the guideline, and a section on guideline methodology.

Received: 17 February 2022; Accepted: 3 June 2022

**Conflicts of interest**

This is a short version of the EuroGuiDerm Guideline on Atopic Eczema. For introductory chapters, methods section and systemic treatment, see part 1 ([https://doi.org/10.1111/jdv.18345](https://doi.org/10.1111/jdv.18345)) or for the long version, methods report (including COI disclosures) and evidence report, see [https://www.edf.one/home/Guidelines/Guidelines.html](https://www.edf.one/home/Guidelines/Guidelines.html).

**Funding sources**

The development of this EuroGuiDerm guideline was funded through the EuroGuiDerm Centre for Guideline Development. The European Dermatology Forum is responsible for fundraising and holds all of the funds it raises in one account. The EuroGuiDerm Team is not involved in fundraising or in decisions about which guidelines (GL) or consensus statements (CS) are funded. These decisions are made by the EuroGuiDerm Board of Directors independently. The EDF and any other body supporting EuroGuiDerm are never involved in developing guidelines and have no say in the content or focus of guidelines.

**Overview of recommendations**

General recommendations for systemic drugs in special atopic eczema patient populations (Table 1) and for topical drugs for treatment of atopic eczema (Table 2) are given below.

| Table 1 | General recommendations for systemic drugs in special AE patient populations (for details see corresponding chapter) |
|-----|------------------------------------------------------------------------------------------------------------------|
| **Children and adolescents with AE who are candidates for systemic treatment** | **Conventional systemic treatments** | **Biologics** | **JAK-inhibitors** | **Rescue therapy** |
|     | Ciclosporin | Methotrexate | Azathioprine | Dupilumab | Tralokinumab | Baricitinib | Upadacitinib | Systemic corticosteroids |
| **Dose for children** |                           |                           |                           |     |     |     |     |     |
| Licensed for a 16 years common use dosage children: 2.5-5 mg/kg per day in two single doses |     |     |     |     |     |     |     |     |
| Off-label: commonly used dosage children: 0.3–0.4 mg/kg per week |     |     |     |     |     |     |     |     |
| Off-label: commonly used dosage children: 1-3 mg/kg per day |     |     |     |     |     |     |     |     |
| Licensed for a 6 years: age 6-11: from 15kg <60kg, initially 300 mg s.c. day 1 1/5 followed by 300 mg Q4W, when ≥60 kg, initially 600 mg s.c. day 1 followed by 300 mg Q2W |     |     |     |     |     |     |     |     |
| Age 12-17: <60 kg: initially 400 mg s.c. day 1 followed by 200 mg Q2W, when ≥60 kg: initially 600 mg s.c. day 1 followed by 300 mg Q2W |     |     |     |     |     |     |     |     |
| Pregnancy (in candidates for systemic treatment) |     |     |     |     |     |     |     |     |
|     |     |     |     |     |     |     |     |     |
| Breastfeeding |     |     |     |     |     |     |     |     |
|     |     |     |     |     |     |     |     |     |

**Symbols and Implications (adapted from GRADE[188])**

- **1**: We believe that almost all informed people who would make this choice.
- **1**: We believe that most informed people who would make this choice, but a substantial number would not.
- **0**: We cannot make a recommendation.
- **1**: We believe that most informed people would make a choice against this intervention, but a substantial number would not.
- **1**: We believe that almost all informed people would make a choice against this intervention.
- **No recommendation.**
### Table 2  General recommendations for topical drugs for treatment of atopic eczema (for details see corresponding chapter)

| Overall recommendation                                                                 | TCS I   | TCS II   | TCS III  | TCS IV  |
|----------------------------------------------------------------------------------------|---------|----------|----------|---------|
| For further information see background text                                              |         |          |          |         |
| class I not suitable for long-term proactive treatment; long-term proactive treatment only class II | TCS class III and IV | Tacrolimus 0.1% | Tacrolimus 0.03% | Pimecrolimus 1% |
| acute flare; proactive treatment with TCS class III class IV not for long term daily treatment or head and neck; class IV not recommended for proactive treatment either | acute flare; long-term proactive treatment; especially in face, intertriginous sites, anogenital area | acute flare; long-term proactive treatment; especially in face, intertriginous sites, anogenital area |
| Most important side effects                                                            |         |          |          |         |
| skin atrophy                                                                            | skin atrophy | telangiectasia | striae distensae | ecchymosis |
| telangiectasia                                                                          | telangiectasia | striae distensae | ecchymosis | hypertrichosis |
| striae distensae                                                                        | striae distensae | ecchymosis | hypertrichosis | perioral dermatitis |
| ecchymosis                                                                              | ecchymosis | hypertrichosis | perioral dermatitis | corticosteroid addiction syndrome |
| hypertrichosis                                                                          | hypertrichosis | perioral dermatitis | corticosteroid addiction syndrome | suppression of adrenal function |
| perioral dermatitis                                                                     | perioral dermatitis | corticosteroid addiction syndrome | suppression of adrenal function | |
| skin atrophy                                                                            | skin atrophy | telangiectasia | striae distensae | ecchymosis |
| telangiectasia                                                                          | telangiectasia | striae distensae | ecchymosis | hypertrichosis |
| striae distensae                                                                        | striae distensae | ecchymosis | hypertrichosis | perioral dermatitis |
| ecchymosis                                                                              | ecchymosis | hypertrichosis | perioral dermatitis | corticosteroid addiction syndrome |
| hypertrichosis                                                                          | hypertrichosis | perioral dermatitis | corticosteroid addiction syndrome | suppression of adrenal function |
| perioral dermatitis                                                                     | perioral dermatitis | corticosteroid addiction syndrome | suppression of adrenal function | |
| TCI class II and III are off label for proactive treatment                              | in label for proactive treatment | not suitable for proactive treatment |
| Special considerations                                                                  |         |          |          |         |
| Suitable for children > 2 to < 16 years of age                                          | yes     | yes     | yes (0.03%)¹  | yes²  |
| Suitable for babies < 2 years of age                                                   | yes     | yes     | under specialist supervision | yes (0.03%)¹  |
| Suitable during pregnancy                                                               | yes     | yes     | yes (0.03% & 0.1%)¹ | yes³ |
| Suitable during breastfeeding                                                           | yes     | yes     | yes (0.03% & 0.1%)¹ | yes³ |
| Suitable for pruritus                                                                  | yes     | yes     | yes (0.03% & 0.1%)¹ | yes³ |

Symbols: Implications (adapted from GRADE ¹⁸⁸)

| 11 | We believe that all or almost all informed people would make this choice. |
| 10 | We believe that most informed people would make this choice, but a substantial number would not. |
| 0  | We cannot make a recommendation. |
| 01 | We believe that most informed people would make a choice against this intervention, but a substantial number would not. |
| 01 | We believe that all or almost all informed people would make a choice against this intervention. |
| No recommendation. | |

**Patients’ perspective**

**We recommend** that health care providers treat each patient as a whole person, not just the skin, while considering the burden of skin disease on life.

100% agreement

Patient/caregiver consensus

**We recommend** that health care providers use the principle of shared decision-making, i.e. discuss the patients’ beliefs, lifestyle and preferences when deciding on a treatment plan.

100% agreement

Patient/caregiver consensus

**We recommend** that patients with co-morbidities are treated by multi-disciplinary teams.

100% agreement

Patient/caregiver consensus

**We recommend** that patients have access to all available treatments and that these treatments are affordable and practical.

100% agreement

Patient/caregiver consensus

**We recommend** that health care providers are given time, training and resources to educate patients/caregivers in lay language about treating and managing their own condition.

100% agreement

Patient/caregiver consensus

**We recommend** that patients/caregivers receive adequate knowledge, skills, resources and support to treat their AE at home and cope with its impact on life.

100% agreement

Patient/caregiver consensus

**We recommend** that patients have access to all available treatments and that these treatments are affordable and practical.

100% agreement

Patient/caregiver consensus

**We recommend** that health care providers are given time, training and resources to educate patients/caregivers in lay language about treating and managing their own condition.

100% agreement

Patient/caregiver consensus

**We recommend** that patients/caregivers receive adequate knowledge, skills, resources and support to treat their AE at home and cope with its impact on life.

100% agreement

Patient/caregiver consensus

**We recommend** that patients have access to all available treatments and that these treatments are affordable and practical.

100% agreement

Patient/caregiver consensus
## Basic emollients and moisturizers

| Recommendation | Consensus | Agreement |
|----------------|-----------|-----------|
| We recommend gentle cleansing and bathing procedures especially in acutely inflamed or superinfected skin in patients with AE. | (18/18) Expert consensus | **100% agreement** |
| **We suggest** bathing in moderately warm water over a short duration of time in patients with AE. | (17/19) Expert consensus | **>75%** |
| We suggest against the use of alkaline soaps in patients with AE. | (19/19) Expert consensus | **100% agreement** |
| We suggest that patients with AE use body care products, for example gentle cleansers that do not contain potent irritants or relevant allergens. | (20/23) Expert consensus | **>75%** |
| We recommend daily use of emollients, liberally and frequently for patients with AE, as basic treatment of the disturbed skin barrier function. | (18/18) Expert consensus | **100% agreement** |
| We suggest using moisturizers with a hydrophilic formula in the summer and moisturizers with a higher lipid content in the winter in patients with AE. | (15/18) Expert consensus | **>75%** |
| We recommend to apply emollients immediately after bathing or showering and soft pat drying ('soak and seal technique'). | (19/19) Expert consensus | **100% agreement** |
| We recommend the use of emollients as background treatment to prevent flares and to reduce the symptoms of AE. | (18/19) Expert consensus | **>75%** |

1 Abstention

### Emollient therapy

#### Basic emollient therapy

Basic emollient therapy is the essence of every treatment of AE. Emollients usually contain a humectant or moisturizer (promoting stratum corneum hydration) such as urea or glycerol and an occludent (reducing evaporation such as lipids or petrolatum). Recently, marketing of non-medicated 'emollients' containing active ingredients has blurred the line between pure emollients working through their physical properties and topical drugs.

Throughout this guideline, 'emollients' are defined as 'topical formulations with vehicle-type substances without active ingredients', whereas 'emollients plus' refers to 'topical formulations with vehicle-type substances plus additional active, non-medicated substances'.

A Cochrane review compared emollients containing moisturizers versus no moisturizer and found that the former were better at reducing investigator-reported severity and led to fewer flares and a reduction in the use of corticosteroids. There have also been studies that have examined the use of glycerol-containing moisturizers versus vehicle or placebo. More participants in the glycerol group noticed skin improvement but the MID (minimal important difference) was not met.

Some studies have investigated oil-containing emollients versus no treatment or vehicle and found no significant differences between the groups. In one study, there were fewer flares in the oil group and reduced use of topical corticosteroids. Overall, topical active treatment combined with emollients was more effective than emollient treatment alone with various outcomes measured.

It is recommended to apply emollients immediately after bathing or showering and soft pat drying. A small study suggests that an emollient applied alone without bathing may have a longer duration as measured by capacitance. Only emollient preparations free of protein allergens or haptens known to cause contact allergy (such as lanolin/wool wax alcohol or preservatives such as methylisothiazolinone) should be used, especially in children under the age of 2. The long-term use of maintenance (e.g. twice weekly) emollient therapy after remission may prolong the duration of flare-free intervals.

The direct, sole use of emollients on inflamed skin is often poorly tolerated, and it is better to treat the acute flare first with anti-inflammatory procedures including wet wraps (see chapter anti-inflammatory treatment). Emollients are the mainstay of management. Hydration of the skin is usually maintained by at least twice daily application of emollients with a hydrophilic base containing for instance 5% urea or glycerol.

Galenic aspects of the formula should be considered with regard to seasonal differences (more hydrophilic in summer, more lipid content preferably in winter). Also, regional aspects of body sites involved play a role (pastes for intertriginous areas, not too greasy for the face).

Depending on the acuity of the skin condition, lipophilic bases may also be helpful, especially in more chronic conditions.
The use of barrier ointments, bath oils, shower gels, emulsions or micellar solutions that enhance the barrier effect is also recommended.

The amount of the topical that is applied is crucial; about 250 g/week are recommended. It may follow the fingertip unit rule: a fingertip unit (FTU) is the amount of ointment expressed from a tube with a 5 mm diameter nozzle and measured from the distal skin crease to the tip of the index finger (ca. 0.5 g); this is an adequate amount for application to two adult palm areas, which is approximately 2% of an adult body surface area.

The cost of quality emollient (low in contact allergens or hazardous substances) therapies often restricts their use because such therapies are considered to be non-prescription drugs (except for paediatric patients in some European countries).

The use of pure oil products such as coconut or olive oil instead of emulsions will dry out the skin and increase transdermal water loss and thus is not recommended.

**Emollients with non-medicated, active ingredients (emollients plus)**

Several non-medicated products for topical treatment of AE contain putative active ingredients but neither fulfill the definition of, nor need a licence as, a topical drug. These products, referred to as ‘emollients plus’ by the European guideline since 2018, may contain, for example, flavonoids such as licochalcone A, saponins and riboflavins from protein-free oat plantlet extracts, bacterial lysates from Aquaphilus dolomiae or Vitreoscilla filiformis species, or a synthetic derivative of menthol such as menthoxypropanediol.

Oral supplementation with unsaturated fatty acids, such as gammalinolenic acid from evening primrose oil or eicosapentaenoic acid from fish oils, has been studied as a way to improve barrier function and enhance patient acceptance, but has shown conflicting results. The efficacy of topical evening primrose oil-containing emollients depends on the choice of vehicle.

To improve the moisturizing effect of the emollient, several ingredients are used such as urea or glycerol or propylene glycol. Emollients can also be enriched by other ingredients such as moisturizers or tannin, ammonium bituminosulfonate, flavonoids or unsaturated fatty acids such as omega-3 or omega-6 compounds.

**Prevention aspect**

Emollients have a definite place in secondary and tertiary prevention in patients with AE. There is controversial evidence on primary preventive effects of emollients: newborns with high risk of atopy/AE who were treated daily with emollients developed less atopic dermatitis or allergic sensitisations in the first year of life. Two larger and longer randomized controlled trials with a less stringent intervention did not confirm these effects. Some experienced clinicians still feel comfortable using emollients in individuals at risk of AE early in life.

**Cleansing and bathing**

Skin hygiene procedures play an important role in the management of AE, especially in infants and young children. Some authors consider alkaline soaps as disadvantageous compared with liquid cleansers with adequate skin surface pH and lipid content. Bathing is regarded as generally superior to washing or showering – especially in young children - also with regard to emotional and psychological interactions between infants and parents. The water temperature should not be too high. A recent systematic review has shown that daily bathing or showering is not associated with changes in disease severity, but three studies with qualitative analysis found an improvement of itch and IGA by bathing. Showering may be permitted.

The skin must be cleansed thoroughly, but gently and carefully, to get rid of crusts and mechanically eliminate bacterial contaminants in case of superinfection. Cleansers with or without antiseptics can be used. The duration of action of antiseptics is rather short, and mechanical cleansing is probably more important. Cleansing agents are available in various galenic forms (syndets, aqueous solutions) and should not be too irritating and should not contain strong allergens. The pH values should be between 5 and 6. A small randomized study regarding the frequency of bathing procedures did not show any difference between twice weekly versus every day.

In infants, it is easier to perform the first stage of gentle cleansing on the nappy mattress rather than directly in the bathtub. The mechanical component of cleaning helps to remove bacteria from the stratum corneum. Further cleansing is followed by a rapid rinse performed in the bath (27–30°C). The short duration of the bath (approx. 5 min) and the use of bath oils (added for the last 2 min of bathing) are aimed at avoiding epidermal dehydration. Topical emollients are preferentially applied directly after a bath or a shower following gentle drying when the skin is still slightly moist. It should be emphasized that most bath oils commercially available in Europe are practically free of proteinaceous allergens.

Recent studies have found no evidence for a benefit of adding bath additives to standard treatment regimens, while another study found that some bathing additives such as dead sea salt, oatmeal or natural oils, may augment the benefit and reduce the need for or side-effects of pharmacological treatments.

The addition of antiseptics such as sodium hypochlorite (bleach bath) has proved helpful and is discussed in the chapter ‘antimicrobial therapy’.

Adding sodium chloride to bathing water containing oil has been recommended because of its keratolytic and skin moisturizing effect in concentrations up to 5%. In adults, higher salt concentrations with the addition of magnesium have been used to mimic the effect of balneotherapy in the dead sea, also together with UV phototherapy (see chapter phototherapy).
Effective topical therapy depends on three fundamental principles: sufficient potency, sufficient dosage and correct application. Current approved topical anti-inflammatory therapies are corticosteroids (TCS), calcineurin inhibitors (TCI) and a phosphodiesterase 4 (PDE-4) inhibitor, which is approved in the European Union but not yet available.

The amount of anti-inflammatory topicals applied should follow the fingertip unit rule (see chapter emollient therapy). Topical treatment should ideally be applied on hydrated skin, especially when using ointments (‘soak and seal’ approach).

Topical anti-inflammatory therapy can be done by two approaches: reactive and proactive management. In the reactive treatment regimen, anti-inflammatory topical therapy is applied to lesional skin only and is stopped or rapidly tapered once visible lesions are cleared or almost cleared. Proactive therapy is defined as a combination of predefined, long-term, anti-inflammatory treatment applied usually twice a week to previously affected areas of skin in combination with liberal daily use of emollients on the entire body. Additionally, it is marked by a predefined appointment schedule for clinical examinations.

The proactive regimen is started after the therapy of the acute flare, when lesions have been successfully treated with regular anti-inflammatory therapy. The duration of proactive management is usually adapted to the severity and persistence of the disease.

Patients with acute, erosive and oozing lesions, as well as paediatric patients, sometimes do not tolerate standard topical application and may first be treated with ‘wet wraps’ until the oozing stops. Where clinically superinfected skin is suspected, adding oral antibiotic cover should be considered. Wet wrap medications are highly effective in acute AE and improve tolerance of emollient application. Wet wrap dressings with diluted or lower potency corticosteroids (group II, III, typical dilutions used are 1:3–1:10, usually just for a few days is sufficient) are a safe crisis intervention treatment of severe and/or refractory flares of AE with temporary systemic bioactivity of the corticosteroids as the only reported serious side-effects. However, this treatment approach is not standardized yet, and the evidence that it is more effective than conventional treatment with topical corticosteroids in AE is not of high quality. Simple or occlusive medications in less sensitive skin areas and for brief time periods may also increase efficacy and speed up lesion resolution.

**Topical corticosteroids**

**Mechanisms of action and efficacy**

Topical corticosteroids (TCS) are a first-line anti-inflammatory treatment, typically applied on acutely inflamed skin according to patient needs (pruritus, sleeplessness and new flare). The lipophilicity and the low-molecular weight of TCS allow good
penetration into the skin and binding to a steroid receptor in the cytoplasm. The CS-receptor complex acts as a transcription factor with dual activity, decreasing the synthesis of proinflammatory cytokines and increasing the synthesis of anti-inflammatory mediators.

The potency of topical corticosteroids is grouped according to Niedner from mild (class I) to super-potent (class IV). This classification is used across Europe and throughout this guideline, except for France, where this classification is similar but in an inverted ranking. The classification used in the US is even different, and recognizes seven groups: from VII (weakest) to I (most potent).

Latest generation TCS with a better risk–benefit ratio are favoured over earlier generation TCS.

**Dosage: acute flare, short term and long term**

When choosing a TCS, in addition to potency the galenic formulation, patient age and area to which the medication will be applied should be considered. In children, low-to-moderate potency TCS should be used routinely. Adolescent and adult patients can use potent to very potent TCS under specialist supervision in an acute flare of AE for a short period of time. Potent and very potent TCS are sometimes also used in younger age groups under specialist supervision.

Treatment of the face and especially the peri-orbital region or other sensitive areas (folds and neck) should be restricted to mild-to-moderate TCS (class I and II). With mild disease activity, a small amount of TCS twice to three times weekly (monthly amounts in the mean range of 15 g in infants, 30 g in children and up to 60–90 g in adolescents and adults, roughly adapted to affected body surface area), associated with a liberal use of daily emollients allows for a good weekly maintenance treatment routine.

Also, patients with moderate or severe AE can benefit from long-term proactive treatment with a moderate to potent TCS. Twice weekly application of fluticasone propionate or methylprednisolone aceponate (TCS class III) has shown a significant reduction in AE-flare recurrence. Outside of the context of clinical trials, similar experience also exists for other class III and even class II TCS.

**Safety**

For further details on the well-established safety considerations of TCS, see the full version of the guideline.

**Monitoring**

Monitoring by physical examination for cutaneous side-effects during long-term use of potent TCS is very important.

Itch, which can be assessed by itch Numeric Rating Scale (NRS), is the key symptom for evaluating the response to treatment, and tapering should not be initiated before the itch has largely resolved. In addition to continuous background emollient skin care, one to two applications of TCS per day may be necessary with low- and mid-potency TCS to reduce the itch at the beginning, but one correctly dosed treatment per day is typically sufficient. Dose tapering is usually performed to avoid rebound flares, although no controlled studies have demonstrated its usefulness. Tapering strategies consist of switching to a less potent corticosteroid or keeping a more potent one while reducing the frequency of application (intermittent regimen). The most constructive way to spare corticosteroids and avoid corticosteroid-related side-effects is to start the anti-inflammatory treatment early and use them intensively during the acute flares.

**Combination with other treatments**

The combination of TCS with topical calcineurin inhibitors (TCI) at the same site does not seem to be useful. At least in paediatric patients with severe AE, the efficacy and safety profile of pimecrolimus cream 1% combined with fluticasone were similar to that of fluticasone alone. Treating sensitive body areas such as the face (with predilection to skin thinning) with TCI while treating other affected body areas with a TCS is a common practice but class I and II TCS can be used equally effectively on the face and neck for acute flares. Initial treatment with TCS may be considered in patients with acute flare to minimize TCI site reactions (stinging and burning).

**Special considerations**

Patient fear of side-effects of corticosteroids (corticophobia) is quite common and should be recognized (e.g. by TOPICOP score) and adequately addressed to improve adherence and avoid undertreatment. In pregnancy and lactation, lower potency TCS should be used where possible (see chapter pregnancy, breastfeeding and family planning).

**Topical calcineurin inhibitors**

**Mechanisms of action and efficacy**

Two topical calcineurin inhibitors (TCI) (tacrolimus ointment and pimecrolimus cream) are licensed for AE treatment. Pimecrolimus 1% cream and tacrolimus 0.03% ointment are approved in the EU from 2 years of age and above. Elidel cream has additionally been approved in Europe down to 3 months of age. Tacrolimus 0.1% ointment is only licensed in patients age 16 years and above. TCI have an immunosuppressive effect by inhibiting the activity of the phosphorylase enzyme calcineurin and thus inhibiting the activation of T lymphocytes. The transdermal penetration of TCI is slower than that of TCS. TCI are a first-line therapy for sensitive areas where TCS use is likely associated with side-effects or in areas where TCS has already caused side-effects. The efficacy of both formulations has been demonstrated against vehicle in clinical trials for short-term (3 weeks) and long-term use up to 1 year.
The efficacy of long-term monotherapy with tacrolimus ointment has been demonstrated in children and adults. In adults, long-term proactive treatment with 0.1% tacrolimus ointment has shown good effectiveness for flare prevention, similar to class III TCS. Proactive tacrolimus ointment, but not pimecrolimus 1% cream, has been shown to be safe and effective for up to 1 year in reducing the number of flares and improving quality of life (QoL) in both adults and children. Pimecrolimus 1% cream has been studied in infants and children in a combination regimen with TCS, the latter being given if a flare occurred. Fewer data are available for children under 2 years of age.

In children, twice-weekly treatment with tacrolimus 0.03% ointment has been reported to reduce the number of flares and to prolong flare free intervals.

Dosage: acute flare, short term and long term

The anti-inflammatory potency of 0.1% tacrolimus ointment is similar to that of a potent corticosteroid (class III), and 0.1% tacrolimus ointment is clearly more effective than 1% pimecrolimus cream.

TCS and TCI can be used in a daily regimen during an acute AE flare. The efficacy of intermittent treatment twice or three times weekly has been investigated in different trials.

Safety

Safety data of both TCI have been reported in many clinical trials and registries, and high-quality long-term safety data have been published from 10-year tacrolimus and 5-year pimecrolimus studies, demonstrating the safety of this anti-inflammatory treatment in daily practice.

None of the TCI induce skin atrophy. This favours their use over TCS in sensitive body areas such as the eyelid region, the perioral skin, the genital area, the axilla region or the inguinal fold, and makes them suitable for long-term management. In addition, the use of TCI may potentially reverse some of the side-effects of TCS when applied on sensitive areas.

After initial concerns from animal studies, resulting in a black box warning from the US Food and Drug Administration (FDA), no convincing evidence for an increased risk of lymphoma has been found in humans. A long-term safety study over 10 years using tacrolimus ointment 0.03% or 0.1% in children did not show an increased risk of cancer or lymphoma. The application of TCI is not associated with an increased risk of non-melanoma skin cancer, other malignancies or photocarcinogenicity. In a retrospective cohort study with more than 90 000 participants and over 10 years follow-up, no increased risk of basal cell carcinoma or squamous cell carcinoma was observed. The JOELLE study investigated the risk of lymphoma and skin cancers with the use of TCI and TCS in a very large cohort of paediatric and adult patients and found a positive association. However, given the study design, confounding factors, such as disease severity, have not been ruled out.

A recent paediatric prospective observational cohort study (APPLES, n = 7954) found no significant association between regular tacrolimus use and lymphoma risk over a 10-year follow-up period. Nevertheless, given that the long-term oral use of ciclosporin (calcineurin inhibitor) is associated with an increased photocarcinogenicity risk in solid organ transplant patients, exposure of the skin to sunlight should be minimized and effective UV protection through the use of sunscreens and appropriate clothing should be recommended in all patients using TCI. Furthermore, the combined use of TCI and phototherapy should be avoided.

Clinicians should be aware of the black-boxed warning on the use of TCI inhibitors and may discuss this with patients to improve adherence, even if observational studies have not found a convincing association between long-term TCI use and cancer development.

Monitoring

Monitoring by physical examination for cutaneous side-effects during long-term treatment with TCS and TCI is important (also see above).

Special considerations

Although TCI are not approved in pregnancy and lactation (see chapter pregnancy, breastfeeding, family planning), off-label use in pregnancy and lactation is possible as there is no teratogenic potential reported for the entire substance class.

Topical phosphodiesterase 4 inhibitors

Mechanisms of action and efficacy

The topical phosphodiesterase 4 (PDE-4) inhibitor crisaborole is approved for treatment of mild-to-moderate AE in patients 2 years of age and older in the United States, Canada, Australia, Israel and Hong Kong. Crisaborole was approved in the European Union in 2020 but is not commercialized in the European market. Therefore, no recommendations are made.

Upcoming topical treatment

Upcoming topical therapies include several topical janus kinase (JAK) inhibitors. First, promising phase II clinical trial data with the topical JAK inhibitor tofacitinib have been published. Despite these promising results, the clinical development programme of tofacitinib has been stopped. Delgocitinib has been approved for use in AE in Japan. In a 4-week study, the selective JAK-1 and JAK-2 inhibitor ruxolitinib showed a similar or even higher efficacy in mild-to-moderate AE compared with triamcinolone cream (group III TCS) and has recently been approved in the United States. Other JAK inhibitors with similar or different selectivity (brepocitinib) are in the pipeline for topical therapy, but none is currently licensed in Europe.
**Antimicrobial treatment**

| **We suggest** | **G** | **We recommend** | **G** |
|----------------|-------|------------------|-------|
| treatment with topical antiseptic drugs – including sodium hypochlorite 0.005% baths - in patients with a history of recurrent skin infections. | ↑ | a short course of systemic antibiotics only in AE patients with extensive clinically superinfected lesions. | ↑↑ |
| 100% agreement | 100% agreement | 100% agreement |
| (24/24) Expert consensus | (25/25) Expert consensus | (25/25) Expert consensus |

**Antibacterial treatment**

| **We suggest against** | **G** | **We recommend** | **G** |
|-------------------------|-------|------------------|-------|
| the long-term application of topical antibiotics, due to the risk of resistance development. | ↓ | to treat eczema herpeticum without delay using systemic antiviral therapy, such as aciclovir. | ↑↑ |
| 100% agreement | 100% agreement |
| (25/25) Expert consensus | (25/25) Expert consensus |

The prevalence of *Staphylococcus aureus* (SA) colonization among patients with AE is typically above 80% for lesional skin and 40% for nonlesional skin versus 10% in healthy individuals, but this depends largely on the culture methods used. The density of the colonization correlates with the disease severity. Topical corticosteroids and calcineurin inhibitors reduce the colonization rate of SA in AE. Although AE patients are prone to SA skin infections, most AE patients colonized by SA do not show overt signs of infection (i.e. weeping, honey-coloured crusts and pustules). Clinical signs of skin inflammation during AE flares may overlap with signs of skin infection, making the diagnosis of skin infection *per se* challenging. Bacterial swabs are commonly unhelpful, as they do not alter the treatment approach, unless the patient is infected with a resistant bacterial species. SA is a major trigger of AE flares, but its role in the development of AE is still debated. There are a number of mechanisms through which SA can drive eczematous inflammation, including the release of superantigen toxins, which enhance T-cell activation of superantigen-specific and allergen-specific T cells, the expression of IgE antistaphylococcal antibodies and increased expression of IL-31 which leads to pruritus and subsequent scratching. Scratching favours binding of SA to the skin, and the increased amount of SA derived ceramidase aggravates the skin barrier defect. Moreover, superantigen production increases the expression of alternative glucocorticoid receptors that do not bind to topical corticosteroids, which leads to treatment resistance. Biofilm formation by AE-associated staphylococci most certainly also plays a major role in the occlusion of sweat ducts and leads to inflammation and pruritus.

**Antiviral treatment**

| **We recommend** | **G** | **We recommend** | **G** |
|------------------|-------|------------------|-------|
| to treat eczema herpeticum without delay using systemic antiviral therapy, such as aciclovir. | ↑↑ | to perform vaccinations in line with national guidelines. | ↑↑ |
| 100% agreement | 100% agreement |

Viral infections, including herpes simplex, varicella zoster, molluscum contagiosum, smallpox and coxsackie viruses, occur more frequently in AE patients than in healthy individuals, with a tendency to disseminated, widespread disease.

**Eczema herpeticum** (EH), a disseminated herpes simplex virus (HSV) infection, is a potentially serious complication of AE that requires immediate medical action. Patients, mostly children, present with disseminated vesicles, fever and lymphadenopathy and can develop complications such as keratoconjunctivitis, meningitis and encephalitis. Predisposing factors of first episode of EH or recurrent EH are early onset and severe or untreated forms of AE with high IgE levels and atopic comorbidities (extrinsic AE). Pretreatment with topical corticosteroids or calcineurin inhibitors is not associated with an increased risk of developing EH. There is no evidence to recommend discontinuation of topical anti-inflammatory treatments during an EH outbreak. Mainstay of EH therapy is systemic treatment with aciclovir or valaciclovir. Treatment should be started immediately once the clinical diagnosis is made.

**Varicella-zoster virus** (VZV) infection in an immunocompetent child is usually a mild, self-limiting disease. This infection is, however, known to facilitate secondary local or systemic bacterial infection and is a particular concern in children with AE. Earlier studies demonstrated the safety and efficacy of VZV vaccination in these children, who appear to benefit from this vaccination. Moreover, in children with AE, the immune response to VZV vaccine is comparable to that in healthy children. Therefore, parents of atopic children should be encouraged to fully immunize their children depending on specific local guidelines.

**Molluscum contagiosum virus** (MCV) infection is in general benign and self-limiting but frequent in patients with severe AE.
A large variety of topical treatments have been reported such as cantharidin, potassium hydroxide, tretinoin cream and topical cidofovir. Physical therapies, including cryotherapy and curettage, are also effective, but not always well tolerated in paediatric patients and usually unnecessary given the self-limiting nature of MCV infections. Topical treatment of AE with TCS should be continued during MCV infection.

**Eczema coxsackium (EC)** is a disseminated form of coxsackie virus infection mostly occurring in children with active AE lesions. The coxsackie virus A6 strain leads to atypical disease manifestations, which are classified as (i) a diffuse form (lesions extended to the trunk), (ii) an acral form (lesions with a mainly acral distribution) or (iii) eczema coxsackium (disseminated lesions on preexisting eczematous areas). This rash may be confused with bullous impetigo or eczema herpeticum. Symptomatic treatment includes topical corticosteroids and wet wrap therapy.

Regional vaccination programmes should be followed by all AE patients as recommended. The denial of vaccination because of diagnosed AE is a misconception possibly leading to fatal consequences.

**Antifungal treatment**

We suggest topical or systemic antifungal therapy in some patients with AE, mainly in those suffering from the “head and neck” variant of AE and with demonstrated IgE-sensitization to Malassezia spp. Despite its role as a commensal on healthy human skin, Malassezia spp. is attributed a pathogenic role in AE, as it may interact with the local skin immune response and barrier function. Through a deficient skin barrier, Malassezia spp. may activate keratinocytes and dendritic cells causing secretion of a range of proinflammatory cytokines including IL-4, IL-13 and IL-17. The most common class of antifungal drugs prescribed for AE patients are azoles, such as ketoconazole and itraconazole, which also have some anti-inflammatory properties. Due to a better benefit:side-effect ratio, imidazole derivates (fluconazole or itraconazole) should be prescribed instead of ketoconazole for systemic treatment. In summary, antifungal treatment with either topical ketoconazole or ciclopiroxolamine or systemic itraconazole or fluconazole can be considered for those patients who suffer from head–neck dermatitis, particularly for those who are characterized by clear IgE-sensitization to Malassezia spp.

**Antipruritic treatment**

Itch is the most important clinical symptom in AE with particular impact on emotional dimensions of perception as compared with other pruritic dermatoses. Most drugs successfully used in AE patients, because they are targeting the inflammation, will also have a measurable effect on the itch. Only a limited number of studies have specifically assessed the antipruritic effect of treatment modalities in AE. The management of itch in AE requires a multidimensional approach that treats itch itself but also the contributing factors, such as dry skin and skin inflammation.

**Antipruritic effect of anti-inflammatory treatment**

Anti-inflammatory agents, whether topical or systemic, reduce skin lesions and significantly relieve itch. Although topical corticosteroids do not act as direct antipruritic agents, several studies have described the anti-inflammatory effect of topical corticosteroids in AE, in which pruritus was one parameter among others studied. Topical calcineurin inhibitors relieve pruritus significantly in AE. Itch is completely relieved after the first days of treatment in both adults and children. Topical calcineurin inhibitors appeared to significantly reduce AE itch by 36% compared with vehicle application.

The systemic anti-inflammatory agent dupilumab showed high effectiveness in reducing itch in AE patients. Similar data exist for other systemic drugs recently licensed for AE treatment, such as tralokinumab, abrocitinib, baricitinib and upadacitinib (see chapters biologics and JAK-Inhibitors).

**Antipruritic treatment**

*We suggest* topical or systemic antifungal therapy in some patients with AE, mainly in those suffering from the “head and neck” variant of AE and with demonstrated IgE-sensitization to Malassezia spp.

| Antifungal treatment | >95% (23/24) Expert consensus | We suggest topical or systemic antifungal therapy in some patients with AE, mainly in those suffering from the “head and neck” variant of AE and with demonstrated IgE-sensitization to Malassezia spp. |
|----------------------|-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

UV phototherapy relieves pruritus in AE, which has been demonstrated in several studies. A systematic review of 19 RCTs suggests
that narrowband UVB and UVA1 are the most effective forms of phototherapy in the treatment of AE, including reduction in itch intensity.\textsuperscript{121} A recent study by Jaworek \textit{et al.}\textsuperscript{122} documented that narrowband UVB reduces itch in AE patients significantly better than ciclosporin.\textsuperscript{122} There are no data specific to using UV phototherapy to treat itch in AE patients that would lead to recommendations that would differ from the general recommendations for using UV phototherapy in the treatment of AE.

\textbf{Systemic antihistamines}

\begin{tabular}{|c|c|}
\hline
\textbf{We suggest against} using first generation systemic antihistamines as a long-term treatment for itch in AE. & 100\% agreement \hline
\end{tabular}

\begin{tabular}{|c|c|}
\hline
\textbf{We suggest against} using second generation systemic antihistamines as a treatment for itch in AE. & >75\% \hline
\end{tabular}

\begin{tabular}{|c|c|}
\hline
\textbf{We suggest} the use of narrowband UVB or UVA1 in children and adolescents after the assessment of skin type (see background text), but frequent and/or protracted treatment cycles should be avoided. & >95\% \hline
\end{tabular}

\textsuperscript{1} Abstention

\textbf{Selective serotonin reuptake inhibitors}

\begin{tabular}{|c|c|}
\hline
\textbf{We suggest against} the use of selective serotonin reuptake inhibitors as a treatment for itch in AE patients. & 100\% agreement \hline
\end{tabular}

\begin{tabular}{|c|c|}
\hline
\textbf{We suggest} that other phototherapy modalities (balneophototherapy, UVAB, BB-UVB, UVA) are to be considered as a second choice. & 100\% agreement \hline
\end{tabular}

\begin{tabular}{|c|c|}
\hline
\textbf{We suggest} co-treatment with topical emollients during phototherapy. & 100\% agreement \hline
\end{tabular}

\begin{tabular}{|c|c|}
\hline
\textbf{We recommend against} the use of prolonged or repeated treatment cycles and maintenance regimens with all phototherapy modalities. & 100\% agreement \hline
\end{tabular}

\begin{tabular}{|c|c|}
\hline
\textbf{We recommend against} the use of all phototherapy modalities in patients with a history of skin cancer and with an increased risk of skin cancer (including photodamaged skin and those on systemic immunsuppressants (see background text)). & 100\% agreement \hline
\end{tabular}

\textbf{Efficacy of different photo(chemo)therapy modalities in clinical trials}

Photo(chemo)therapy can be used in patients with moderate-to-severe AE recalcitrant to topical therapy. Background information on photobiology, UV modalities and practical aspects can be found in Appendix I in the full version of the guideline. Further information on the systematic review of Garristen \textit{et al.} is found in the full guideline version.\textsuperscript{121} We must, however, emphasize that the use of phototherapy for AE is largely empiric and based on relatively few evidence-based data. There is a clear need for further research on the effectiveness and safety of phototherapy in AE, given that it is frequently used in AE patients.\textsuperscript{136}
Safety of different photo(chemo)therapy modalities in clinical trials

It is evident that our current knowledge on the safety of phototherapy in patients with AE is poor because there are no data from RCTs or registries enrolling large patient cohorts and with prolonged follow-up.

The cancerogenic risk of PUVA is well demonstrated in psoriatic patients, and therefore caution is also recommended in AE patients.\textsuperscript{137–139} However, extrapolating the magnitude of the risk observed with PUVA in patients with psoriasis to the risk in patients with AE is not always correct because psoriatic patients (historically) may have been treated more often with immunosuppressants and/or mutagenic drug therapies.

In patients who use systemic immunosuppressants, especially ciclosporin and azathioprine, phototherapy is not recommended based on their risk of co-carcinogenicity (see chapter conventional systemic drugs).\textsuperscript{140} There are few papers available on combination therapy and long-term safety in psoriatic patients\textsuperscript{141,142}; no papers were found specifically for AE (see separate Appendix I of the full version of the guideline).

Avoidance techniques in atopic eczema

| Recommendation | Level of agreement |
|----------------|--------------------|
| We recommend to identify individual trigger factors in patients with AE, to avoid these in the future, with the aim of prolonging remission or clearance. | ≥75% | (16/17) Expert consensus |
| We recommend to avoid pollen, house dust mite and animal dander as much as possible to prevent exacerbations of AE in sensitized patients with a clear history of skin exacerbation. | ≥75% | (14/15) Expert consensus |
| There is no need to restrict normal everyday physical activity in patients with AE. | Statement | (17/19) Expert consensus |
| We recommend avoiding irritant clothing (e.g. wool with coarse fibers) to prevent an exacerbation of AE in patients with sensitive skin. | ≥75% | (16/17) Expert consensus |
| We suggest that patients with AE learn strategies to cope with stress (e.g. educational programmes). In selected cases, counselling or psychotherapy is suggested. | 100% agreement | (16/16) Expert consensus |

House dust mite avoidance

House dust mite (HDM)-related flares may occur in AE patients. Some house dust mite allergens identified by specific IgE or skin prick testing are enzymatically active compounds, which can destroy the cutaneous permeability barrier and may evoke the development of eczematous inflammation in sensitized atopic individuals.

The evidence on HDM avoidance techniques in the prevention of atopic flares is somewhat controversial.\textsuperscript{143–145} Measures to reduce exposure include mattress encasing, the use of adequate indoor ventilation (filter, well-aeration), and the avoidance of wall washing on high temperature.\textsuperscript{157} HDM, a common indoor allergen occurring in dust, may be reduced by cleaning regularly. Complete eradication by encasing, for example, is not possible.

Animal dander avoidance

When allergies to furry animals are evident, their avoidance is recommended.\textsuperscript{157} Exposure to cat allergens in particular may be a risk factor for developing inflammatory skin lesions and respiratory symptoms in sensitized patients with AE.\textsuperscript{146} There may be an exception for dogs due to a suggested general protective effect of dog-keeping in the development of AE.\textsuperscript{147}

Exercise/perspiration/physical activity

In AE patients, heat and excessive sweating are one of the main factors reported to exacerbate itch.\textsuperscript{148} When excessive sweat is left on the skin, it can lead to occlusion of the sweat pores and formation of keratin plugs which in turn may cause local inflammation and itch. Some of the components of sweat include histamin, antimicrobial peptides and proteases which can induce itch. Sweat can also facilitate the penetration of allergens through the defective atopic skin barrier leading to mast cell degranulation.\textsuperscript{149,150} As sweat is important for skin homeostasis, it is not possible to avoid sweating completely. However, it should be washed off with consistent application of emollients as soon as possible to avoid inducing itch. The evidence concerning physical activity as a trigger for AE is conflicting and incomplete.\textsuperscript{148} Although physical activity often leads to sweating, it is important for both physical and mental health, and AE patient should not be advised to avoid it.
Clothing
In patients with AE, certain fabrics such as wool can cause a tingling sensation, skin irritation and itch. The evidence is not completely clear on which fabrics to recommend and which to avoid. Clothing-related exacerbation can be subjective.\textsuperscript{151} There is no evidence from high-quality studies that certain fabrics decrease the severity of AE.\textsuperscript{151,152} In general, textiles with course fibres, such as certain wool garments and occlusive clothing leading to overheating, should be avoided. Otherwise, the choices of clothing should be based on individual preferences. Most AE patients tolerate silk and cotton well, whereas contact with wool is frequently irritating.

Psychological stress
There is good evidence that AE is associated with depression, anxiety and reduced QoL.\textsuperscript{153,154} It is difficult to investigate whether the psychological stress is a cause or consequence of the AE exacerbation, and in many cases, it is probably both. There is a positive correlation between maternal stress and offspring AE.\textsuperscript{155,156} Although evidence from larger studies is lacking, patients report that stress induces itch and flaring of the disease\textsuperscript{157,158} (see chapter psychological intervention).

Tobacco smoke
The association of AE with active smoking was found to be significant in a meta-analysis (OR 1.87, 95% confidence interval 1.32–2.63). This association remained significant when looking at only children, only adults and by geographic region. Moreover, the effect of exposure to passive smoke on AE flares is small but also significant (OR 1.18, 95% confidence interval 1.01–1.38). Passive smoke was associated with the prevalence and severity of AE both in children and in adults.\textsuperscript{159} The results of a recent registry study of 908 patients with atopic eczema suggest that the intensity of lesions and the Patient Global Assessment Score (PGA) were higher in smoking patients (n = 352) than in non-smoking patients (n = 556). However, physician-assessed disease severity (oSCORAD and EASI scores) did not differ between smokers and non-smokers in this study.\textsuperscript{160}

Dietary interventions in atopic eczema
We recommend to identify individual dietary trigger factors in patients with AE, to avoid these in the future, with the aim of prolonging remission or clearance.\textsuperscript{15} We cannot make a recommendation on probiotics for the management of AE.

IgE-mediated food allergy (immediate reactions):
We recommend diagnostic procedures for the elucidation of IgE-mediated food allergy (food specific IgE and/or SPT, diagnostic elimination diets and challenge tests) in AE patients with a history of food-induced immediate symptoms.

IgE-mediated food allergy (immediate reactions) plus food-induced AE “delayed hypersensitivity”:
We recommend diagnostic procedures for the elucidation of combined reactions to foods (immediate reactions plus food-induced eczema (food specific IgE and/or SPT, diagnostic elimination diets and challenge tests)) in AE patients with a history of food-induced symptoms, including worsening of AE.

History or suspicion of food-triggered AE “delayed hypersensitivity”:
We suggest diagnostic procedures for the elucidation of food as a trigger factor of AE (food specific IgE and/or SPT, diagnostic elimination diets and challenge tests) in patients with moderate-to-severe AE and with a history or suspicion of food-triggered AE.

A therapeutic elimination diet is recommended after the individual diagnosis of food allergy or food–induced eczema in AE.

We recommend re-evaluation of a child’s IgE mediated food allergy after one to two years after strict elimination diet.

We recommend against general dietary interventions (e.g., other supplements, general avoidance of certain foods e.g. cow’s milk, gluten) for the management of AE.
Food allergens, pre- and probiotics

Food allergy has been documented in approximately one-third of children with moderate–to-severe AE.\textsuperscript{161,162} Among food allergens, cow’s milk, hen’s egg, peanut, soya, nuts and fish are most frequently responsible for immediate-type food allergy and AE exacerbation in young children, with age-dependent variations in causally incriminated food.\textsuperscript{163} In older children, adolescents and adults pollen-associated food allergy should also be taken into account.\textsuperscript{164–166}

For further details on response patterns to food allergens, see the full version of the guideline.

Pre- and probiotics and dietary supplements

Probiotics such as lactobacillus mixtures have been studied in AE and have been shown to induce improvement in some settings.\textsuperscript{167} Other studies failed to show significant effects.\textsuperscript{168,169} In a study with 800 infants, the effect of a prebiotic mixture was investigated and found to have beneficial effects in preventing the development of AE.\textsuperscript{170} A recent Cochrane review identified 39 randomized controlled trials involving 2599 randomized participants.\textsuperscript{171} The authors concluded that compared with no probiotic, currently available probiotic strains probably make little or no difference in improving patient-rated eczema symptoms. However, in 2020, the systematic review by Tan-Lim et al found that certain probiotic preparations (\textit{Bifidobacterium animalis subsp lactis} CECT 8145, \textit{Bifidobacterium longum} CECT 7347, and \textit{Lactobacillus casei} casei DN-114001) show benefit in reducing allergic symptoms in paediatric AE.\textsuperscript{172}

A systemic review on dietary supplements including fish oil, vitamin D or vitamin E came to the conclusion that there is no convincing evidence of the benefit of dietary supplements in AE.\textsuperscript{173}

Allergen-specific immunotherapy

The cause of symptoms in allergic patients is that the sensitized individual reacts with an allergic immune response to an otherwise harmless allergen. The aim of allergen-specific immunotherapy (AIT) is to theoretically cure allergic diseases. The role of allergen sensitization in AE pathogenesis has been investigated but remains to be fully elucidated. Inflammatory processes seem to be mediated by both an immediate-type reaction, initiated by the internalization of the complex IgE specific/allergens from epidermal dendritic cells, and a delayed T-cell reactivity, characterized by a Th2 inflammatory pattern.\textsuperscript{133}

One of the most important allergen sources in AE are HDM due to the perennial exposure. Recent studies have also focused on the role of pollen allergens as a trigger for AE flare-ups. AIT consists of administering increasing doses of allergen to modulate the response and promote peripheral immune tolerance mechanisms. AIT induces a shift from a Th2 to a Th1 immune response pattern, a decrease of mediator release from mast cells and the production of blocking antibodies IgG4.

Complementary medicine

We recommend against vitamins as a treatment for AE.

We recommend against acupuncture as standard therapy for AE.

We recommend against phytotherapy as standard therapy for AE.

We recommend against blood autologous serum as standard therapy for AE.

We recommend against Chinese herbal medicine as standard therapy for AE.

We cannot make a recommendation with respect to alpine climate therapy for AE.
Complementary medicine describes a wide variety of healthcare practices used alongside standard medical treatment. These include alternative health approaches such as traditional Chinese medicine, acupuncture, autologous blood therapy, phytotherapy and high-altitude alpine climate. Overall, the evidence to support any of these treatments for AE was not strong enough. Further details on our critical appraisal are found in the full version of the guideline.

**Psychological and educational interventions**

![Image](https://via.placeholder.com/150)

**We suggest** that therapeutic patient education programmes with proven efficacy in children and adults with AE are widely implemented.

Psychological and emotional factors as well as psychodynamic structures within the family are well-known elements that may influence the clinical course of AE. Stress can elicit severe exacerbations of the disease and perpetuate the itch-scratch cycle. Anxiety or depression are acknowledged comorbidities in AE patients. Furthermore, poor QoL and adherence to treatment are key issues in these patients. As a multidimensional phenomenon, low treatment adherence is influenced by factors such as the disease itself, its chronicity but also by the patient’s beliefs and characteristics. It can be improved by introducing specific strategies after understanding the patient’s adherence pattern. Therapeutic patient education (TPE) programmes were originally designed to enable people with chronic diseases to manage their illness (increasing autonomy and decreasing medical complications). They can help patients and their families to better understand and accept their disease and cope with treatment in order to improve QoL and treatment adherence. The aim of TPE is not simply to provide information by leaflets, but entails the transfer of skills (e.g. disease self-management strategies, knowledge of treatments, relaxation and behavioural therapy techniques) from a trained healthcare professional to the patient or their parents. Additionally, as TPE is patient-centred holistic care, it should facilitate a better partnership between doctors and their patients/caregivers. TPE can also help restore family dynamics. Parents with negative treatment experiences in the past and poor coping abilities regarding scratch control are likely to benefit most from TPE programmes.

High-quality TPE programmes should ideally be evidence-based, tailored to a patient’s needs, taking into account the individual educational and cultural background (rather than being standardized in form and content). It should also have well-defined content and activities that are provided by an interdisciplinary healthcare team.

There is also some evidence for nurse- and psychologist-led programmes as well as e-health education. For further details see the full version of the guideline.

Structured interdisciplinary high-quality education programmes should be implemented regardless of the severity of AE. They can improve the efficacy of topical treatment and be particularly helpful in evaluating the next treatment steps, like the necessity of introducing systemic treatments. Psychological interventions, for example autogenic training, relaxation, cognitive-behavioural therapy, habit reversal and behavioural therapies have a positive effect on different aspects of AE.

**Pregnancy, breastfeeding and family planning**

The current ethical framework of GCP guidelines deems it unethical to perform clinical trials in pregnant women. Therefore, there is no high-level evidence on efficacy and safety in this patient population. AE is the most common general skin disease in pregnancy. AE may either (i) worsen in women with a chronic condition, or (ii) may be reactivated in patients with a past AE history or (iii) may occur in women with no AE history (atopic eruption of pregnancy, AEP). Worsening of AE is mostly reported during the second and third trimesters, while AEP typically occurs during the first trimester. There are no major clinical differences between classical AE worsening and AEP. Physiological skewness of the immune system towards a Th2-dominated response during pregnancy as well as physical and psychological stress during this period may contribute to AE worsening during pregnancy. Little is known about treatment patterns during pregnancy, but patients and caregivers tend to reduce the use of topical and systemic therapies to avoid presumed harm to the fetus. Consequently, undertreatment of AE during pregnancy may lead to serious QoL impairment but also to complications such as eczema herpeticum or *Staphylococcus aureus* skin infections, and should therefore be avoided.

**Pregnant women**

In pregnant women with AE, **we recommend** TCS class II or III.

| In pregnant women with AE, we recommend TCS class II or III. | 100% agreement |
| --- | --- |
| 14/14 | Expert consensus |

In pregnant women with AE, **we suggest** that TCI may preferably be used on the face and intertriginous areas and on abdominal, breast and thigh skin, where the risk of striae formation increases with excessive use of TCS.

| In pregnant women with AE, we suggest that TCI may preferably be used on the face and intertriginous areas and on abdominal, breast and thigh skin, where the risk of striae formation increases with excessive use of TCS. | 100% agreement |
| --- | --- |
| 19/19 | Expert consensus |

In pregnant women with AE, when topical treatments are insufficient, **we recommend** narrow-band UVB (311 nm) or broad spectrum UVB therapy if NB-UVB is unavailable.

| In pregnant women with AE, when topical treatments are insufficient, we recommend narrow-band UVB (311 nm) or broad spectrum UVB therapy if NB-UVB is unavailable. | 100% agreement |
| --- | --- |
| 19/19 | Expert consensus |
First-line treatments

Emollients. Basic emollient therapy is key in the treatment of AE also during pregnancy and must be proposed to pregnant women with AE as a basic daily therapy. There is no firm evidence on which emollient should be used, but using one with a high lipid content and as few potentially harmful agents as possible is recommended. Using emollients in a wet wrap technique is encouraged.5

TCS. Reactive or proactive use of TCS class II or III is recommended. A Cochrane systematic review updated in 2015 including 14 studies (5 cohort and 9 case–control studies) with 1 601 515 study subjects has examined the risk of TCS use in pregnancy. Overall, it has been deemed safe, with no causal associations between maternal exposure to TCS of all potencies and pregnancy outcomes including mode of delivery, congenital abnormalities, preterm delivery, fetal death, and low Apgar score, although the use of very potent topical corticosteroids may be associated with low birthweight.180 Proactive, twice weekly TCS application as maintenance therapy is regarded as safe, but caution is recommended when using potent TCS over large body surface areas, or sensitive areas such as breast and thigh skin, on a more regular basis. Some experts suggest that class IV may be used as rescue therapy, or over longer periods on limited skin areas, but this is controversial. Fluticasone propionate should be avoided as it is the only TCS that is known not to be metabolized by the placenta.88

TCI. Reactive and proactive use of TCI may be preferable on the face and intertriginous areas, and on abdominal, breast and thigh skin, where the risk of striae formation increases with excessive use of TCS.

Antiseptics. Antiseptics, except triclosan, may be used by pregnant women if clinically needed to prevent recurring skin infections, but are not recommended as a general routine measure.

UV phototherapy. Therapy with narrowband UVB (311 nm) and broad-spectrum UVB does not impose a risk to the fetus in pregnant woman. However, oral psor alien should not be used preconceptionally (3 months) or in pregnant women.

Second- and third-line treatments

Second- and third-line treatments are recommended in pregnant women with AE who are inadequately controlled with TCS class II or III.

Systemic corticosteroids should not be used in the long-term in AE in general and even more so not during pregnancy, as it is associated with an increased risk of fetal complications, including gestational diabetes.180 Only short courses of prednisolone (maximum 0.5 mg/kg/d) may be used with strict indication. Ciclosporin may be used off-label in severe uncontrolled AE during pregnancy if topical anti-inflammatory treatment alone or in combination with UV treatment failures, and there is a clear need for better long-term disease control. However, extra attention should be given to the renal function and blood pressure of the mother. There is no evidence of teratogenicity. Ciclosporin crosses the placenta181 and should not be used during pregnancy, unless the potential benefit to the mother justifies the potential risk to the fetus.

AZA may be used off-label in pregnant women with severe uncontrolled AE who are already receiving this treatment at the time of conception. There is no evidence for teratogenicity from studies with patients with inflammatory bowel diseases. Closely consulting an experienced obstetrician when prescribing this drug is strongly recommended.88

MTX and mycophenolate mofetil are teratogenic and therefore strictly contraindicated during pregnancy.
We cannot recommend any of the novel systemic medications, as there are currently no clinical data available to inform about any potential drug-associated risks. Pre-clinical data do not indicate that there would be a teratogenic potential of dupilumab or tralokinumab if given during pregnancy.

Abrocitinib, baricitinib and upadacitinib are contraindicated during pregnancy according to label. There are no clinical data but single case reports supporting its safety in pregnant women, but teratogenic effects have been described in animal models.

Antihistamines are of limited efficacy in AE (see chapter antipruritic treatment). In case of need, loratadine should preferentially be used because of the broad experience with this drug in pregnant women.

Due to lack of experience with crisaborole during pregnancy, this drug should not be used preconceptionally, in pregnancy or during lactation.

Specific consideration for breastfeeding women

TCS and TCI: No studies have examined the safety of TCS and TCI use during lactation but no harmful effect is suspected. Nevertheless, it is recommended to apply the topical treatment in the nipple region immediately after nursing the child, to allow the drug to be absorbed into the skin before the next feeding.  

Systemic corticosteroids: Treatment with a short course of a systemic corticosteroids during lactation is safe, since <0.1% of the mother’s ingested dosage is secreted into breastmilk.

MTX, AZA, ciclosporin and JAK inhibitors are secreted in breastmilk and may induce immunosuppression in the neonate. MTX, AZA, ciclosporin and JAK inhibitors are generally not recommended for lactating mothers.

Family planning

| In parents with AE planning to have a child, we recommend TCS II or III or TCI. | 100% agreement |
|---|---|
| In women with AE planning to have a child, we recommend stopping methotrexate at least 3 months before conception.* | >75% |
| In men with AE planning to have a child, we recommend stopping methotrexate 3 months before conception.* | 100% agreement |

*EMA recommends 6 months as a means of precaution, the practice of the guideline group differs from this.

Preconception recommendations for women

TCS and TCI: Although the literature on this subject is very sparse, topical AE therapies in women wishing to conceive can be used without concern.

MTX: Local labels in different countries suggest a contraindication range spanning from 1 month to 6 months before conception. The European Medicines Agency (EMA) recommends 6 months as a means of precaution. The practice of the guideline group differs from this, and we recommend stopping methotrexate 3 months before conception.

Preconception recommendations for men

TCS and TCI: Although the literature on this subject is very sparse, topical AE therapies in men wishing to father a child can be used without concern.

Ciclosporin may be used in the treatment of AE in men at the time of conception, as there is no evidence for harm or decreased fertility.

MTX: Following the European S3-guideline on systemic treatment of psoriasis vulgaris, a 3-month MTX pause prior to conception is recommended. However, (inadvertent) exposure beyond this time does not justify termination of pregnancy, because there is no evidence of male teratogenicity.

AZA and baricitinib: there is no contraindication for the use of AZA and baricitinib in men wishing to father a child.
Considerations for paediatric and adolescent patients

AE may appear during the first months of life, and most patients develop the condition before the age of 5 years. Around 60% of children outgrow AE in some cases. However, significant numbers present with either AE or hand eczema as adults.182

Severe early disease and a family history of AE may predict a more persistent course.13

During infancy (0–2 years), the predilection areas are the cheeks, head, trunk, and extensor surfaces of the extremities, although flexural involvement is also common, which becomes an even more prominent feature during later childhood.

The first clinical signs often appear on the cheeks in form of erythematos, oozing, crusted plaques. The symptoms may then generalize and spread to the scalp, forehead, trunk and limbs. Centrifugal pallor along with spared area of the nose and paranasal skin cause the ‘headlight sign’ appearance. The diaper area is also usually intact in infancy. The facial symptoms usually decrease by the end of the first year.183

Prematurity causes barrier dysfunction with higher transepidermal water loss (TEWL) and increased percutaneous absorption of chemicals. This is an important factor when planning local treatment dosage, body area, and duration. Infants are more susceptible to percutaneous toxicity. Their high surface area-to-volume ratio, immature drug metabolism systems, and decreased subcutaneous fat stores increase the absorption potential of the skin, while decreasing the volume of distribution of a drug or toxin. In full-term infants, skin barrier development continues during the first year of life.

Bathing an infant provides important psychological benefits between parent and child. Bathing of infants with AE should be brief to maintain the microbial flora, which changes with age, avoiding harsh soaps and detergents and using bath emollients to aid skin hydration and emollients as soap substitutes to aid barrier function.184

Wet wraps can be a useful treatment approach where additional hydration of the skin is needed, in particular in young children.44

With mild disease activity, maintenance use of topical corticosteroid twice to three times weekly (monthly amounts in the mean range of 15 g in infants, 30 g in children and up to 60–90 g in adolescents and adults, adapted to affected body surface area) with a liberal use of emollients do not result in adverse systemic or local effects.13

To treat the face of a 3-month-old infant, 1 FTU will suffice. To fully cover an entire leg of a 6-year-old, a 4 FTU dose is used.

TCI may effectively and safely be used as anti-inflammatory agents in the treatment of AE, especially on sensitive skin areas (e.g. face), from age two. The use of TCI in younger children is common.132 Daily application (BID) is recommended during relapses on the affected area, following the FTU rules, while according to the proactive regimen they may also be applied twice a week on the symptom-free areas.13 TCI are also used under 2 years of age in many centres.

**Occupational aspects**

| AE can have a negative impact on work life and is associated with a higher risk of hand eczema. |
| Statement |
| 100% agreement |
| (15/15) Expert consensus |

| We suggest individual pre-employment counselling regarding choice of profession, including risk assessment, avoidance strategies and protective measures. |
| Statement |
| 100% agreement |
| (23/23) Expert consensus |

A number of occupational aspects are relevant to AE patients, as they run a significant risk of developing occupational contact dermatitis. Atopy amplifies the effects of irritant and allergen exposure in several professions such as hairdressers, nurses, metal-workers, mechanics and cleaners, where hand eczema is a very

| Table 3 Occupations with an elevated risk of hand eczema |
|---|
| **Job/occupation** | **Possible sensitizing compounds and atopic eczema triggers** |
| Hairdresser | Hair dyes, perm products, haircare products, rubber auxiliary materials, bleaching agents, detergents, wet-work, cosmetic preservatives |
| Beauticians | Acrylics, acrylates, cosmetic preservatives, rubber auxiliary materials, wet-work |
| Cleaning and housekeeping | Disinfectants, rubber auxiliary materials, abrasives, wet-work |
| Baker | Flour and grain dust, rubber auxiliary materials, wet-work |
| Painter | Paints, isocyanates, resins, turpentine, paint pigments, preservatives |
| Construction and cement worker | Isocyanates, cement, concrete, glue, paints, resins, fibreglass, and metals |
| Carpenter | Woods |
| Agricultural worker | Animal particles, disinfectants, plants, rubber auxiliary materials |
| Florist and gardener | Plants, rubber auxiliary materials, wet-work |
| Healthcare worker | Latex, disinfectants, rubber auxiliary materials, medications, wet-work |
| Veterinarian, animal lab worker, zookeeper | Animal particles, disinfectants, rubber auxiliary materials, medications, tools, wet-work |
| Catering and cooking employees | Detergents, disinfectants, foods, rubber auxiliary materials, wet-work |
| Wind energy technician | Solvents, glues, paints, epoxy, resins, fibreglass, acids and alkalis, detergents |
| Mechanic and metal worker | Cutting fluids, coolants, detergents, metals, petroleum products, preservatives |
The risk of hand eczema in AE patients is increased about fourfold. Physicians should inform AE patients about the increased risk, and provide good guidance about prophylactic skin protection and irritant/contact allergen avoidance. All dermatologists treating adolescent patients with AE should advise these early on occupational aspects of their skin disease and suitable career choices. For further information on impact of AE on work life, see Table 3 and the full version of the guideline.

**Strengths and limitations**

The vision of this guideline was to provide a comprehensive evidence-based update on all aspects of AE care with high relevance to practising clinicians across Europe. To reflect the latest methodological rigour in guideline development, the formal structure of the guideline document has been changed to follow the structure and style of the EuroGuiDerm guidelines. We assembled a guideline development group (GDG) that included clinical and methodological experts from across Europe, including patients. Our clear conflict of interest policy has created more transparency and was also reflected in the online voting procedures on standardized guideline statements.

While this regulated process of guideline formation has resulted in higher methodological rigour, independence, objectivity and quality of the content, we are conscious that the guideline document is already outdated regarding the fastest changing content, in particular the chapter on systemic therapy. However, we plan to update the content of this aspect of the guideline on a regular basis, creating a ‘living’ guideline for systemic AE therapies.

**Acknowledgement**

Open Access funding enabled and organized by Projekt DEAL.

**Data availability statement**

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

**References**

1. Loden M, Andersson AC, Anderson C et al. A double-blind study comparing the effect of glycerin and urea on dry, eczematous skin in atopic patients. *Acta Derm Venereol* 2002; 82: 45–47.
2. Darsow U, Lübke J, Taieb A et al. Position paper on diagnosis and treatment of atopic dermatitis. *J Eur Acad Dermatol Venereol* 2005; 19: 286–295.
3. Wollenberg A, Barbarot S, Bieber T et al. Consensus-based European guidelines for treatment of atopic dermatitis (atopic dermatitis) in adults and children: part I. *J Eur Acad Dermatol Venereol* 2018; 32: 657–682.
4. van Zuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen A, Arents BWM. Emollients and moisturisers for eczema. *Cochrane Database Syst Rev* 2017; 2: CD012119.
5. Boralevi F, Saint Aromon M, Delarue A et al. Long-term emollient therapy improves xerosis in children with atopic dermatitis. *J Eur Acad Dermatol Venereol* 2014; 28: 1456–1462.
6. Schram ME, Spuls PJ, Leeﬂang MM, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. *Allergy* 2012; 67: 99–106.
7. Akerstrom U, Reitamo S, Langeland T et al. Comparison of moisturizing creams for the prevention of atopic dermatitis relapse: a randomized double-blind controlled multicentre clinical trial. *Acta Derm Venereol* 2015; 95: 587–592.
8. Chiang C, Eichenfield L F. Quantitative assessment of combination bathing and moisturizing regimens on skin hydration in atopic dermatitis. *Pediatr Dermatol* 2009; 26: 273–278.
9. Dinkloh A, Worm M, Geier J, Schau A, Wollenberg A. Contact sensitization in patients with suspected cosmetic intolerance: results of the IVDK 2006-2011. *J Eur Acad Dermatol Venereol* 2015; 29: 1071–1081.
10. Mengeaud V, Phulpin C, Bacqué A, Boralevi F, Schmitt AM, Taieb A. An innovative oat-based sterile emollient cream in the maintenance therapy of childhood atopic dermatitis. *Pediatr Dermatol* 2015; 32: 208–215.
11. Angelova-Fischer I, Rippke F, Richter D et al. Stand-alone emollient treatment reduces ﬂares after discontinuation of topical steroid treatment in atopic dermatitis: a double-blind, randomized, vehicle-controlled, Left-right Comparison Study. *Acta Derm Venereol* 2018; 98: 517–523.
12. Wollenberg A, Schnopp C. Evolution of conventional therapy in atopic dermatitis. *Immunol Allergy Clin North Am* 2010; 30: 351–368.
13. Wollenberg A, Barbarot S, Bieber T et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. *J Eur Acad Dermatol Venereol* 2018; 32: 850–878.
14. Gelmetti C, Wollenberg A. Atopic dermatitis – all you can do from the outside. *Br J Dermatol* 2014; 170(Suppl 1): 19–24.
15. National Institute for Health and Care Excellence. NICE pathways: eczema. Vol. 03.08.2021, 2020.
16. Mandeau A, Aries MF, Boe JF et al. Rhetbal(R) oat plantlet extract: evidence of protein-free content and assessment of regulatory activity on immune inﬂammatory mediators. *Planta Med* 2011; 77: 900–906.
17. Gueniche A, Knaudt B, Schuck E et al. Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study. *Br J Dermatol* 2008; 159: 1357–1363.
18. Aries MF, Hernandez-Pigeon H, Vaisserie C et al. Anti-inﬂammatory and immunomodulatory effects of Aquaphilus dolomiae extract on in vitro models. *Clin Cosmet Investig Dermatol* 2016; 9: 421–434.
19. Bamford JT, Ray S, Musekiwa A, van Gool C, Humphreys R, Ernst E. Oral evening primrose oil and borage oil for eczema. *Cochrane Database Syst Rev* 2013; CD004416.
20. Gehring W, Bopp R, Rippke F, Gloo M. Effect of topically applied evening primrose oil on epidermal barrier function in atopic dermatitis as a function of vehicle. *Arzneimittel Forschung* 1999; 49: 635–642.
21. Simpson EL, Chalmers JR, Hanifin JM et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. *J Allergy Clin Immunol* 2014; 134: 818–823.
22. Horimukai K, Morita K, Narita M et al. Immune inflammatory mediators. *Allergy* 2009; 642.
23. Skjerven HO, Rehblinder EM, Vettukattil R et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. *Lancet* 2020; 395: 951–961.
24. Uehara M, Takada K. Use of soap in the management of atopic dermatitis. *Clin Exp Dermatol* 1985; 10: 419–425.
25. Blume-Peytavi U, Cork MJ, Faergemann J, Szczapa J, Vanaclocha F, Gelmetti C. Bathing and cleansing in newborns from day 1 to first year of life: recommendations from a European round table meeting. *J Eur Acad Dermatol Venereol* 2009; 23: 751–759.
27 Koutoulis I, Pyle T, Kopylov D, Little A, Gaughan J, Kratimenos P. The association between bathing habits and severity of atopic dermatitis in children. Clin Pediatr (Phila) 2016; 55: 176–181.

28 Denda M, Sokabe T, Fukumi-Tominaga T, Tominaga M. Effects of skin surface temperature on epidermal permeability barrier homeostasis. J Invest Dermatol 2007; 127: 654–659.

29 Hua T, Yousaf M, Gwillim E et al. Does daily bathing or showering worsen atopic dermatitis severity? A systematic review and meta-analysis. Arch Dermatol Res 2020; 313: 729–735.

30 Ring J, Alomar A, Bieber T et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part II. J Eur Acad Dermatol Venereol 2012; 26: 1176–1193.

31 Koutoulis I, Petrova K, Kratimenos P, Gaughan J. Frequency of bathing in the management of atopic dermatitis: to bathe or not to bathe? Clin Pediatr (Phila) 2014; 53: 677–681.

32 Ring J, Mohrenschlager M. Allergy to peanut oil—clinically relevant? J Eur Acad Dermatol Venereol 2007; 21: 452–455.

33 Santer M, Ridd MJ, Francis NA et al. Emollient bath additives for the treatment of childhood eczema (BATHE): multicentre pragmatic parallel-group randomised controlled trial of clinical and cost effectiveness. BMJ 2018; 361: k3132.

34 Maarouf M, Hendricks AJ, Shi VY et al. Six topical steroids in the treatment of atopic dermatitis of childhood. J Eur Acad Dermatol Venereol 2009; 23: 1356–1361.

35 Ludwig G. On the topical effect of sea water tub-baths with and without addition of an oil emulsion. Zeitschrift für Haut- und Geschlechtskrankheiten 1968; 43: 683–688.

36 Dittmar HC, Pflieger D, Schempp CM, Schopf E, Simon JC. Comparison of nabuliphototherapy and UVA/B mono-phototherapy in patients with subacute atopic dermatitis. Hautarzt 1999; 50: 649–653.

37 Wollenberg A, Oranje A, Deleuran M et al. ETFAD/EADV eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol 2016; 30: 729–747.

38 Wollenberg A, Frank R, Kroth J et al. Proactive therapy of atopic eczema—a evidence-based concept with a behavioral background. J Dtsch Dermatol Ges 2009; 2009: 117–121.

39 Wollenberg A, Ehmann LM. Long term treatment concepts and proactive therapy for atopic dermatitis. Annals Dermatol 2012; 24: 253–260.

40 Schnopp C, Holtmann C, Stock S et al. Topical steroids under wet-wrap dressings in atopic dermatitis—a vehicle-controlled trial. Dermatology 2002; 204: 56–59.

41 Gonzalez-Lopez G, Ceballos-Rodriguez RM, Gonzalez-Lopez JF, Feito Rodriguez M, Herranz-Pinto P. Efficacy and safety of wet therapy for patients with atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol 2016; 177: 688–695.

42 Kohl LL, Kang Y, Antaya RJ. A randomized, controlled trial comparing topical steroid application to wet versus dry skin in children with atopic dermatitis (AD). J Am Acad Dermatol 2016; 75: 306–311.

43 Jazmohamed SR, Oranje AP, Devillers AC et al. The proactive wet-wrap method with diluted corticosteroids versus emollients in children with atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2014; 70: 1076–1082.

44 Cadmus SD, Sebastian KR, Warren D et al. Efficacy and patient opinion of wet-wrap dressings using 0.1% triamcinolone acetonide ointment vs cream in the treatment of pediatric atopic dermatitis: a randomized split-body control study. Pediatric Dermatol 2019; 36: 437–441.

45 Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002; 147: 528–537.

46 Berth-Jones J, Damstra RJ, Golsch S et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double-blind, parallel group study. BMJ 2003; 326: 1367–1360.

47 Niedner R. Therapie mit systemischen Glukokortikoiden. Hautarzt 2001; 52: 1062–1071.

48 Barnes L, Kaya G, Rollason V. Topical corticosteroid-induced skin atrophy: a comprehensive review. Drug Saf 2015; 38: 493–509.

49 Van Der Meer JB, Glazenburg EJ, Mulder PG, Eggink HF, Coenraads PJ. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands adult atopic dermatitis study group. Br J Dermatol 1999; 140: 1114–1121.

50 Quelle C, Pommarede R, Saurat JH. Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood. Pediatr Dermatol 1984; 1: 246–255.

51 Charman C, Williams H. Use of corticosteroids and corticosteroid phobia in atopic dermatitis. Clin Dermatol 2003; 21: 193–200.

52 Meurer M, Eichenfeld LF, Ho V, Potter PC, Werfel T, Hultsch T. Addition of pimecrolimus cream 1% to a topical corticosteroid treatment regimen in paediatric patients with severe atopic dermatitis: a randomised, double-blind trial. J Dermatol Treat 2010; 21: 157–166.

53 Stalder JF, Aubert H, Anthoine E et al. Topical corticosteroid phobia in atopic dermatitis: international feasibility study of the TOPICOP score. Allergy 2017; 72: 1713–1719.

54 Aubert-Wastiaux H, Moret L, Le Rhun A et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. Br J Dermatol 2011; 165: 808–814.

55 Lee JY, Her Y, Kim CW, Kim SS. Topical corticosteroid phobia among parents of children with atopic eczema in Korea. Annals Dermatol 2015; 27: 499–506.

56 Müller SM, Tomaszchetti D, Euler S, Vogt DR, Herzog L, Itin P. Topical corticosteroid concerns in dermatological outpatients: a cross-sectional and interventional study. Dermatology 2016; 232: 444–452.

57 Carr WW. Topical calcineurin inhibitors for atopic dermatitis review and treatment recommendations. Paediatr Drugs 2013; 15: 303–310.

58 Norris DA. Mechanisms of action of topical therapies and the rationale for combination therapy. J Am Acad Dermatol 2005; 53: S17–S25.

59 Ruzicka T, Bieber T, Sicco P et al. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 1997; 337: 816–821.

60 Van Leent EJ, Graber M, Thurston M, Wagenaar A, Spuls PI, Bos JD. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998; 134: 805–809.

61 Reitamo S, Wollenberg A, Sicco P et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European tacrolimus ointment study group. Arch Dermatol 2000; 136: 999–1006.

62 Meurer M, Folster-Holst R, Wozel G et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002; 205: 271–277.

63 Reitamo S, Van Leent EJ, Ho V et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 539–546.

64 Curry Martins J, Martins C, Aoki V, Gois AF, Ishii HA, da Silva EM. Topical tacrolimus for atopic dermatitis. Cochrane Database Syst Rev 2015: CD009864.

65 Chen SL, Yan J, Wang FS. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. J Dermatol Treat 2010; 21: 144–156.

66 Wollenberg A, Reitamo S, Atzori F et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy 2008; 63: 742–750.

67 Thaci D, Reitamo S, Gonzalez Ensenat MA et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol 2008; 159: 1348–1356.

68 Ho VC, Gupta A, Kaufmann R et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003; 142: 155–162.

69 Eichenfeld LF, Lucky AW, Boguniewicz M et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and
moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46: 495–504.

Patel RR, Vander Straten MR, Korman NJ. The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis. Arch Dermatol 2003; 139: 1184–1186.

Reitamo S, Mandelin J, Rubins A et al. The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis. Int J Dermatol 2009; 48: 348–355.

Abedi N, Pawliczak R. Efficacy and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis: meta-analysis of randomized clinical trials. Potent Dermatologi i Allergologi 2019; 36: 752–759.

Reitamo S, Rustin M, Harper J et al. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. Br J Dermatol 2008; 159: 942–951.

Sigurgeirsson B, Boznanski A, Todd G et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics 2015; 135: 597–606.

Reitamo S, Rissanen J, Raimondi D et al. The new topical ascomycin derivative SDZ ASM 901 does not induce skin atopy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001; 144: 507–513.

Hong CH, Gooderham M, Bissonnette R. Evidence review of topical Calcineurin inhibitors for the treatment of adult atopic dermatitis. J Cutan Med Surg 2019; 23: 5–10s.

Ohtsuki M, Morimoto H, Nakagawa H. Tacrolimus ointment for the treatment of moderate-to-severe atopic dermatitis in children and adolescents. J Am Acad Dermatol 2020; 83: 375–381.

Ring J, Barker J, Behrendt H et al. Review of the potential photocarcinogenicity of topical calcineurin inhibitors: position statement of the European dermatology forum. J Eur Acad Dermatol Venereol 2005; 19: 663–671.

Margolis DJ, Hoffstad O, Bilker WB. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007; 214: 289–293.

Thaci D, Salgo R. Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies. Clin Dermatol 2010; 28: 52–56.

Margolis DJ, Abuabara K, Hoffstad OJ, Wan J, Raimondi D, Bilker WB. Association between malignancy and topical use of Pimecrolimus. JAMA Dermatol 2015; 151: 594–599.

Deleuran M, Vestergaard C, Velund A, Thestrup-Pedersen K. Topical Calcineurin inhibitors, topical glucocorticoids and cancer in children: a Nationwide study. Acta Derm Venereol 2016; 96: 834–835.

Asgari MM, Tsai AL, Avalos L, Sokil M, Quesenberry CP Jr. Association between topical Calcineurin inhibitor use and keratinocyte carcinoma risk among adults with atopic dermatitis. JAMA Dermatol 2020; 156: 1066–1073.

Castellsague J, Kuiper JG, Pottegard A et al. A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (joint European longitudinal lymphoma and skin cancer evaluation – JOELLE study). Clin Epidemiol 2018; 10: 299–310.

Czarnecka-Operacz M, Jenerowicz D. Topical calcineurin inhibitors in the treatment of atopic dermatitis – an update on safety issues. J Dtsch Dermatol Ges 2012; 10: 167–172.

Vestergaard C, Wollenberg A, Barbarot S et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. J Eur Acad Dermatol Venereol 2019; 33: 1644–1659.

Bissonnette R, Papp KA, Poulin Y et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol 2016; 175: 902–911.

Nakagawa H, Nemoto O, Igarashi A, Nagata T. Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study. Br J Dermatol 2018; 178: 424–432.

Kim BS, Howell MD, Sun K, Papp K, Nasir A, Kuligowski ME. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol 2020; 145: 572–582.

Torté JE, van der Felzt W, Hennekam M, van Bemkum A, van Zaeren El, Pasmans SG. Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol 2016; 175: 687–695.

Alexander H, Paller AS, Traidl-Hoffmann C et al. The role of bacterial skin infections in atopic dermatitis: expert statement and review from the international eczema council skin infection group. Br J Dermatol 2020; 182: 1331–1342.

Cornelissen C, Marguardt Y, Czaia K et al. IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. J Allergy Clin Immunol 2012; 129: 33.e1–33.e8.

Schlievert PM, Case LC, Strandberg KL, Abrams BB, Leung DYM. Superantigen profile of Staphylococcus aureus isolates from patients with steroid-resistant atopic dermatitis. Clin Infect Dis 2008; 46: 1562–1567.

Wollenberg A, Zoeh C, Wetzel S, Plevig W, Przybilla B. Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases. J Am Acad Dermatol 2003; 49: 198–205.

Schröder M, Worm M, Werfel T et al. Recurrent eczema herpeticum - a retrospective European multicenter study evaluating the clinical characteristics of eczema herpeticum cases in atopic dermatitis patients. J Eur Acad Dermatol Venereol 2020; 34: 1074–1079.

Ong PY, Leung DY. Bacterial and viral infections in atopic dermatitis: a comprehensive review. Clin Rev Allergy Immunol 2016; 51: 329–337.

Kreth HW, Hoeger PH. Safety, reactogenicity, and immunogenicity of live attenuated varicella vaccine in children between 1 and 9 years of age with atopic dermatitis. Eur J Pediatr 2006; 165: 677–683.

Schneider L, Wetnberg A, Boguniewics M et al. Immune response to varicella vaccine in children with atopic dermatitis compared with non-atopic controls. J Allergy Clin Immunol 2010; 126: 7106–7.e2.

Osier E, Eichenfield L. The utility of Cantharidin for the treatment of Molluscum Contagiosum. Pediatr Dermatol 2015; 32: 295–296.

Wollenberg A, Wetzel S, Burgdorf WH, Haas J. Viral infections in atopic dermatitic: pathogenic aspects and clinical management. J Allergy Clin Immunol 2003; 112: 667–674.

Mathes EF, Oza V, Frieden IJ et al. "Eczema coxsackium" and unusual cutaneous findings in an enterovirus outbreak. Pediatrics 2013; 132: e149–e157.

Neri I, Dondi A, Wollenberg A et al. Atypical forms of hand, foot, and mouth disease: a prospective study of 47 Italian children. Pediatr Dermatol 2016; 33: 429–437.

Lynch MD, Sears A, Cookson H et al. Disseminated coxsackievirus A6 affecting children with atopic dermatitis. Clin Exp Dermatol 2015; 40: 525–528.

Johnson VK, Hayman JL, McCarthy CA, Cardona ID. Successful treatment of adult and pediatric atopic dermatitis: review on safety and benefits. JAMA Dermatol 2015; 151: 834–835.

Sparber F, De Gregorio C, Steinkolber S et al. The skin commensal yeast Malassezia triggers a type 17 response that coordinates anti-fungal immunity and exacerbates skin inflammation. Cell Host Microbe 2019; 25: 389–403.e6.

Thammahong A, Kiatsurayanon C, Edwards SW, Rerknimitr P, Chiewchongchol D. The clinical significance of fungi in atopic dermatitis. Int J Dermatol 2020; 59: 926–935.
147 Pelucchi C, Galeone C, Bach JF, Lu Vecchia C, Chatenoud L. Pet exposure and risk of atopic dermatitis at the pediatric age: a meta-analysis of birth cohort studies. *J Allergy Clin Immunol* 2013; 132: 616–22.e7.

148 Kim A, Silverberg JI. A systematic review of vigorous physical activity in eczema. *Br J Dermatol* 2016; 174: 660–662.

149 Murota H, Yamaga K, Ono E, Katayama I. Sweat in the pathogenesis of atopic dermatitis. *Exp Dermatol* 2019; 28: 1416–1421.

150 Jaros J, Wilson C, Shi YY. Fabric selection in atopic dermatitis: an evidence-based review. *Am J Clin Dermatol* 2020; 2: 467–482.

151 Lopes C, Silva D, Delgado L, Correia O, Moreira A. Functional textiles for atopic dermatitis: a systematic review and meta-analysis. *Pediatr Allergy Immunol* 2013; 24: 603–613.

152 Bao Q, Chen L, Lu Z et al. Association between eczema and risk of depression: a systematic review and meta-analysis of 188,495 participants. *J Affect Disord* 2018; 238: 458–464.

153 Ronnstad ATM, Halling-Overgaard AS, Hamann CR, Skov L, Egeberg A, Thyssen JP. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis. *J Am Acad Dermatol* 2018; 79: e30.

154 Chan CWH, Law BMH, Liu YH et al. The association between maternal stress and childhood eczema: a systematic review. *Int J Environ Res Public Health* 2018; 15: 1–17.

155 Flanigan C, Sheikh A, DunnGalvin A, Brew BK, Almqvist C, Nwaru BI. Why does sweat lead to the development of itch in atopic dermatitis? *Exp Dermatol* 2019; 28: 1416–1421.

156 Makgeorgeu A, Leonardi-Bee J, Bath-Hextall FI et al. Probiotics for treating eczema. *Cochrane Database Syst Rev* 2018; 11: Cd006135.

157 Senra MS, Wollenberg A. Psychodermatological aspects of atopic dermatitis. *Clin Exp Allergy* 2018; 48: 403–414.

158 Flanigan C, Sheikh A, DunnGalvin A, Brew BK, Almqvist C, Nwaru BI. Prenatal maternal psychosocial stress and offspring’s asthma and allergic disease: a systematic review and meta-analysis. *Clin Exp Allergy* 2018; 48: 403–414.

159 Mochiruki H, Lavery MJ, Nattkemper LA et al. Impact of acute stress on itch sensation and scratching behaviour in patients with atopic dermatitis and healthy controls. *Br J Dermatol* 2019; 180: 821–827.

160 Oh SH, Bae BG, Park CO et al. Association of stress with symptoms of atopic dermatitis. *Acta Derm Venereol* 2010; 90: 582–588.

161 Kantor R, Kim A, Thyssen JP, Silverberg JJ. Association of atopic dermatitis with smoking: a systematic review and meta-analysis. *J Am Acad Dermatol* 2016; 75: 1119–1125.e1.

162 Pilz AC, Schielein MC, Schuster B et al. Atopic dermatitis: disease characteristics and comorbidities in smoking and non-smoking patients from the TREATgermany registry. *J Eur Acad Dermatol Venereol* 2022; 36: 413–421.

163 Zhang T, Marks T, Mohsin M et al. Does atopic dermatitis cause food allergy? A systematic review. *J Allergy Clin Immunol* 2016; 137: 1071–1078.

164 Eigenmann PA, Sicherer SH, Borkowski TA, Cohen BA, Sampson HA. Prevalence of IgE-mediated food allergy among children with atopic dermatitis. *Pediatrics* 1998; 101: E8.

165 Sicherer SH, Sampson HA. Food hypersensitivity and atopic dermatitis: pathophysiology, epidemiology, diagnosis, and management. *J Allergy Clin Immunol* 1999; 104: S114–S122.

166 Breuer K, Heratizadeh A, Wolff A et al. Late eczematous reactions to food in children with atopic dermatitis. *Clin Exp Allergy* 2004; 34: 817–824.

167 Reekers R, Busche M, Wittmann M, Kapp A, Werfel T. Birch pollen-related foods trigger atopic dermatitis in patients with specific cutaneous T-cell responses to birch pollen antigens. *J Allergy Clin Immunol* 1999; 104: 466–472.

168 Wassmann-Otto A, Heratizadeh A, Wichmann K, Werfel T. Birch pollen-related foods can cause late eczematous reactions in patients with atopic dermatitis. *Allergy* 2018; 73: 2046–2054.

169 Isolauri E, Arvola T, Sütas Y, Moilanen E, Salminen S. Probiotics in the management of atopic eczema. *Clin Exp Allergy* 2000; 30: 1604–1610.

170 Fölsner-Holst R, Müller F, Schnopp N et al. Prospective, randomized controlled trial on lactobacillus rhamnosus in infants with moderate to severe atopic dermatitis. *Br J Dermatol* 2006; 155: 1256–1261.

171 Rosenfeldt V, Benfeldt E, Nielsen SD et al. Effect of probiotic lactobacillus strains in children with atopic dermatitis. *J Allergy Clin Immunol* 2003; 111: 389–395.

172 Grüber C. Probiotics and probiotics in allergy prevention and treatment: future prospects. *Expert Rev Clin Immunol* 2012; 8: 17–19.

173 Hamann CR, Egeberg A, Gislason G, Skov L, Thyssen JP. Pregnancy complications, treatment characteristics and birth outcomes in women with atopic dermatitis in Denmark. *J Eur Acad Dermatol Venereol* 2019; 33: 2253–2263.

174 Stalder JF, Bernier C, Ball A et al. Therapeutic patient education in atopic dermatitis: worldwide experiences. *Pediatr Dermatol* 2013; 30: 329–334.

175 Senra MS, Wollenberg A. Psychodermatological aspects of atopic dermatitis. *Acta Derm Venereol* 2014; 104: 991–999.

176 Makgeorgeu A, Leonardi-Bee J, Bath-Hextall FI et al. Probiotics for treating eczema. *Cochrane Database Syst Rev* 2018; 11: Cd006135.

177 Fölsner-Holst R, Müller F, Schnopp N et al. Prospective, randomized controlled trial on lactobacillus rhamnosus in infants with moderate to severe atopic dermatitis. *Br J Dermatol* 2006; 155: 1256–1261.

178 Geraci D, Casula M, Nocito S et al. Probiotics for atopic dermatitis: a randomized controlled trial. *Int J Dermatol* 2016; 55: 493–499.

179 Hamann CR, Egeberg A, Gislason G, Skov L, Thyssen JP. Pregnancy complications, treatment characteristics and birth outcomes in women with atopic dermatitis in Denmark. *J Eur Acad Dermatol Venereol* 2019; 33: 577–587.

180 Reekers R, Busche M, Wittmann M, Kapp A, Werfel T. Birch pollen-related foods trigger atopic dermatitis in patients with specific cutaneous T-cell responses to birch pollen antigens. *J Allergy Clin Immunol* 1999; 104: 466–472.

181 Wassmann-Otto A, Heratizadeh A, Wichmann K, Werfel T. Birch pollen-related foods can cause late eczematous reactions in patients with atopic dermatitis. *Allergy* 2018; 73: 2046–2054.

182 Reekers R, Busche M, Wittmann M, Kapp A, Werfel T. Birch pollen-related foods trigger atopic dermatitis in patients with specific cutaneous T-cell responses to birch pollen antigens. *J Allergy Clin Immunol* 1999; 104: 466–472.

183 Wassmann-Otto A, Heratizadeh A, Wichmann K, Werfel T. Birch pollen-related foods can cause late eczematous reactions in patients with atopic dermatitis. *Allergy* 2018; 73: 2046–2054.